PhotoBiotics’ awarded a TSB Biomedical Catalyst Feasibility Award

London, November 2012: 
PhotoBiotics have been awarded a Technology Strategy Board Biomedical Catalyst Feasibility award to carry out a 1 year R&D study to explore applications of its OptiLink™ platform.

The Technology Strategy Board (TSB)1 Biomedical Catalyst funding scheme is the UK government's flagship scheme to support its biotechnology industry. The Feasibility award allows companies to explore high-risk, high-gain R&D concepts that could add value, intellectual property and opportunities for their business. It is a completive process where less than third of the applications are funded. Some 22 SME-led applications shared an overall pot of £29m for Round 1 of the scheme.

Dr Deonarain comments "This scheme has been a real boon for the industry, allowing companies like us to take some risk with only a small, 25% financial outlay. If successful, our OptiLink™ technology will be even more valuable and allow us to exploit our expertise with a wider range of potential biopharma partners".